New prospects for PCSK9 inhibition
- Landmesser, Ulf
- Chapman, M. John
- Stock, Jane K.
- Amarenco, Pierre
- Belch, Jill J. F.
- Borén, Jan
- Farnier, Michel
- Ference, Brian A.
- Gielen, Stephan
- Graham, Ian
- Grobbee, Diederick E.
- Hovingh, G. Kees
- Luscher, Thomas F.
- Piepoli, Massimo F.
- Ray, Kausik K.
- Stroes, Erik S.
- Wiklund, Olov
- Windecker, Stephan
- Zamorano, Jose Luis
- Pinto, Fausto
- Tokgozoglu, Lale
- Bax, Jeroen J.
- Catapano, Alberico L.
Publication date
July 2018
DOIAbstract
This commentary refers to ‘2017 update of ESC/EAS task force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia’, by U Landmesser et al., doi: 10.1093/eurheartj/ehx549
Add to ORKG